Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.47 |
| ▸ | DRD2 | P14416 | 9/20 | 0.47 |
| ▸ | HTR1A | P08908 | 6/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184238 | 0.96 | HTR2A (0.47) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6186709 | 0.95 | HTR2A (0.46) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6188819 | 0.92 | HTR2A (0.46) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6187016 | 0.90 | HTR2A (0.52) | HTR2ADRD2HTR1A | |
| SCHEMBL6186005 | 0.88 | HTR2A (0.46) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6187114 | 0.87 | HTR2A (0.45) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6264654 | 0.86 | HTR2A (0.51) | HTR2ADRD2HTR1AHTR7 | |
| SCHEMBL6186307 | 0.85 | HTR2A (0.54) | HTR2ADRD2HTR1A | |
| SCHEMBL6186374 | 0.85 | DRD2 (0.51) | HTR2ADRD2HTR1AHTR7 | |
| SCHEMBL6190118 | 0.82 | HTR2A (0.54) | HTR2ADRD2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546145-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029048-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | DAVIS JAMIE MARIE (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | HTR2C, CNR1, HTR2A | HTR2A 3/4885DRD2 4/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.